Key personnel

  • Chair - Mr Justin Vale, consultant surgeon, Imperial College Healthcare NHS Trust 
  • Project manager - Elizabeth Pegers

Introduction to the pathway group

The LCA urology cancer pathway group is part of the second wave of LCA pathway groups and met for the first time in June 2013. The group has set out its aims to improve patient access, experience and outcomes for urology cancer patients across south and west London. The membership of the group brings together specialist expertise from secondary and tertiary care as well as allowing for the future involvement of primary care representatives, patients and users of the services to enable development of high quality patient-centred care.

The urology cancer pathway group supports the aims and objectives of the London Cancer Alliance in providing world class cancer services across south and west London. It aims to improve cancer patients' experience and outcomes through delivering excellence in clinical care, research, innovation and education with particular emphasis on earlier diagnosis for urology cancers.


  • Draw on the highest levels of expertise in its decision making.
  • Review evidence and current performance of pathways within the LCA with regard to outcomes, Model of Care recommendations and best practice.
  • Develop improvement plans and make recommendations for improvement to the Clinical Board.
  • Undertake a baseline audit of the performance of each organisation against delivery of the relevant Model of Care recommendations. The audit will include review against the Model of Care co-dependency framework
  • Agree and establish current best practice, and develop an exemplar best practice pathway for all tumour types.
  • Be compliant with peer review requirements and create action plans where appropriate to address gaps in service provision.
  • Existing guidelines for each cancer network within the LCA should be merged to produce a single document used across the LCA. If these do not already exist, the pathway group should produce a new set of guidelines for the LCA on its specific tumour site or pathway.
  • Ensure the appropriate level of engagement with patients, primary care and other key stakeholders, such as public health, ensuring bi-annual stakeholder events.


  • To develop and ensure compliance against a best practice prostate pathway which will reduce waiting times to treatment for all patients urgently referred for suspicion of cancer by their GP.
  • To develop criteria for and implement risk stratified follow up for prostate cancer patients. Allowing for better utilisation of clinic resources and reducing unnecessary clinic appointments for patients.
  • Reconfiguring specialist renal MDTs from three providers to two, ensuring every patient has input from a wide number of clinical specialities and experience.
  • Improve urology cancer patient experience and outcomes through delivering excellence in research, innovation and education.
  • Reduce variation throughout the LCA by monitoring quality metrics and ensuring there are no outliers who are consistently providing poor patient outcomes and care.
  • Improve early diagnosis and detection by participating in national and local initiatives to increase the number of patients presenting to their GP earlier with symptoms. 
  • Develop strong links with cross cutting palliative care and survivorship groups to improve patient experience.
  • Improve communication between tertiary treating centres and secondary care to enable more robust referral pathways and comprehensive local follow up.
  • Respond to the Model of Care recommendations regarding the centralisation of centres for surgery, undertaking full analysis of available options to ensure robust decision making.
Close ×